Serum contents of endocannabinoids are correlated with blood pressure in depressed women

Lipids in Health and Disease

Volumn 11, Issue , 2012, Pages

  Ho, W S Vanessa ^a,c   Hill, Matthew N ^b,d   Miller, Gregory E ^b   Gorzalka, Boris B ^b   Hillard, Cecilia J ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^d UNIVERSITY OF CALGARY   (Canada)

Author keywords

2 arachidonoylglycerol; Anandamide; Cardiovascular risk; Depression; Diastolic blood pressure; Systolic blood pressure

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ANANDAMIDE; ENDOCANNABINOID; BIOLOGICAL MARKER;

ARTICLE; BLOOD LEVEL; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; BODY MASS; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; CLINICAL ARTICLE; DEPRESSION; DIASTOLIC BLOOD PRESSURE; FEMALE; HUMAN; MAJOR DEPRESSION; MEAN ARTERIAL PRESSURE; SYSTOLIC BLOOD PRESSURE; ADULT; BLOOD; CASE CONTROL STUDY;

ADULT; BIOLOGICAL MARKERS; BLOOD PRESSURE; CASE-CONTROL STUDIES; DEPRESSION; ENDOCANNABINOIDS; FEMALE; HUMANS;

EID: 84857410633     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-11-32     Document Type: Article

References (46)

1. Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat. Navarro M, Hernandez E, Munoz RM, del Arco I, Villanua MA, Carrera MR, et al. Neuroreport 1997 8 491 496 10.1097/00001756-199701200-00023 9080435 (Pubitemid 27180108)
2. Involvement of CB1 cannabinoid receptors in emotional behaviour. Martin M, Ledent C, Parmentier M, Maldonado R, Valverde O, Psychopharmacology (Berl) 2002 159 379 387 10.1007/s00213-001-0946-5 (Pubitemid 34143362)
3. Endocannabinoid signaling negatively modulates stress-induced activation of the hypothalamic-pituitary-adrenal axis. Patel S, Roelke CT, Rademacher DJ, Cullinan WE, Hillard CJ, Endocrinology 2004 145 5431 5438 10.1210/en.2004-0638 15331569 (Pubitemid 39564580)
4. Inhibition of restraint stress-induced neural and behavioural activation by endogenous cannabinoid signalling. Patel S, Roelke CT, Rademacher DJ, Hillard CJ, Eur J Neurosci 2005 21 1057 1069 10.1111/j.1460-9568.2005.03916.x 15787710 (Pubitemid 40461057)
5. Downregulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress. Hill MN, Patel S, Carrier EJ, Rademacher DJ, Ormerod BK, Hillard CJ, et al. Neuropsychopharmacology 2005 30 508 515 10.1038/sj.npp.1300601 15525997 (Pubitemid 40271153)
6. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Di Marzo V, Fontana A, Cadas H, Schinelli S, Cimino G, Schwartz JC, et al. Nature 1994 372 686 691 10.1038/372686a0 7990962
7. Activation of PAF receptors results in enhanced synthesis of 2-arachidonoylglycerol (2-AG) in immune cells. Berdyshev EV, Schmid PC, Krebsbach RJ, Schmid HH, Faseb J 2001 15 2171 2178 10.1096/fj.01-0181com 11641243 (Pubitemid 32927934)
8. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. Cota D, Marsicano G, Tschop M, Grubler Y, Flachskamm C, Schubert M, et al. J Clin Invest 2003 112 423 431 12897210 (Pubitemid 38063771)
9. The role of endogenous cannabinoids in the hypothalamo-pituitary-adrenal axis regulation: in vivo and in vitro studies in CB1 receptor knockout mice. Barna I, Zelena D, Arszovszki AC, Ledent C, Life Sci 2004 75 2959 2970 10.1016/j.lfs.2004.06.006 15454346 (Pubitemid 39349260)
10. Serum endocannabinoid content is altered in females with depressive disorders: a preliminary report. Hill MN, Miller GE, Ho WS, Gorzalka BB, Hillard CJ, Pharmacopsychiatry 2008 41 48 53 10.1055/s-2007-993211 18311684 (Pubitemid 351427522)
11. Circulating endocannabinoids and N-acyl ethanolamines are differentially regulated in major depression and following exposure to social stress. Hill MN, Miller GE, Carrier EJ, Gorzalka BB, Hillard CJ, Psychoneuroendocrinology 2009 34 1257 1262 10.1016/j.psyneuen.2009.03.013 19394765
12. CNR1 gene is associated with high neuroticism and low agreebleness and interacts with recent negative life events to predict current depressive symptoms. Juhasz G, Chase D, Pegg E, Downey D, Toth ZG, Stones K, et al. Neuropsychopharmacology 2009 34 2019 2027 10.1038/npp.2009.19 19242408
13. Cannabinoid receptor 1 (CNR1) gene: impact on antidepressant treatment response and emotion processing in major depression. Domschke K, Dannlowski U, Ohrmann P, Lawford B, Bauer J, Kugel H, et al. Eur Neuropsychopharmacology 2008 18 751 759 10.1016/j.euroneuro.2008.05.003
14. Depression as a risk factor for cardiac mortality and morbidity: a review of potential mechanisms. Carney RM, Freedl KE, Miller GE, Jaffe AS, J Psychosom Res 2002 53 897 902 10.1016/S0022-3999(02)00311-2 12377300 (Pubitemid 35282619)
15. Depression, heart rate variability, and acute myocardial infarction. Carney RM, Blumenthal JA, Stein PK, Watkins L, Catellier D, Berkman LF, et al. Circulation 2001 104 2024 2028 10.1161/hc4201.097834 11673340 (Pubitemid 33027041)
16. Lifetime history of depression and carotid atherosclerosis in middle-aged women. Jones DJ, Bromberger JT, Sutton-Tyrrell K, Matthews KA, Arch Gen Psychiatry 2003 60 153 160 10.1001/archpsyc.60.2.153 12578432 (Pubitemid 36173121)
17. Baroreflex sensitivity is reduced in depression. Broadley AJ, Frenneaux MP, Moskvina V, Jones CJ, Korszun A, Psychosom Med 2005 67 648 651 10.1097/01.psy.0000170829.91643.24 16046382 (Pubitemid 41033598)
18. Blood pressure regulation by endocannabinoids and their receptors. Pacher P, Batkai S, Kunos G, Neuropharmacology 2005 48 1130 1138 10.1016/j.neuropharm. 2004.12.005 15910888 (Pubitemid 40725985)
19. Mechanisms of anandamide-induced vasorelaxation in rat isolated coronary arteries. White R, Ho WS, Bottrill FE, Ford WR, Hiley CR, Br J Pharmacol 2001 134 921 929 10.1038/sj.bjp.0704333 11606334 (Pubitemid 33016165)
20. 2-Arachidonoylglycerol, a candidate of endothelium-derived hyperpolarizing factor. Kagota S, Yamaguchi Y, Nakamura K, Sugiura T, Waku K, Kunitomo M, Eur J Pharmacol 2001 415 233 238 10.1016/S0014-2999(01)00833-0 11275004 (Pubitemid 32239469)
21. Cannabinoids acting on CB1 receptors decrease contractile performance in human atrial muscle. Bonz A, Laser M, Kullmer S, Kniesch S, Babin-Ebell J, Popp V, et al. J Cardiovasc Pharmacol 2003 41 657 664 10.1097/00005344-200304000- 00020 12658069 (Pubitemid 36373805)
22. Cardiovascular effects of anandamide in anesthetized and conscious normotensive and hypertensive rats. Lake KD, Martin BR, Kunos G, Varga K, Hypertension 1997 29 1204 1210 9149688 (Pubitemid 27198232)
23. Cardiovascular effects of 2-arachidonoyl glycerol in anesthetized mice. Jarai Z, Wagner JA, Goparaju SK, Wang L, Razdan RK, Sugiura T, et al. Hypertension 2000 35 679 684 10679517 (Pubitemid 30108168)
24. Inhibition of exocytotic noradrenaline release by presynaptic cannabinoid CB1 receptors on peripheral sympathetic nerves. Ishac EJ, Jiang L, Lake KD, Varga K, Abood ME, Kunos G, Br J Pharmacol 1996 118 2023 2028 8864538 (Pubitemid 26292572)
25. Effects of cannabinoids on sympathetic and parasympathetic neuroeffector transmission in the rabbit heart. Szabo B, Nordheim U, Niederhoffer N, J Pharmacol Exp Ther 2001 297 819 826 11303075 (Pubitemid 32378017)
26. Human platelets bind and degrade 2-arachidonoylglycerol, which activates these cells through a cannabinoid receptor. Maccarrone M, Bari M, Menichelli A, Giuliani E, Del Principe D, Finazzi-Agro A, Eur J Biochem 2001 268 819 825 10.1046/j.1432-1327.2001.01942.x 11168423 (Pubitemid 32862642)
27. Estrogen stimulates arachidonoylethanolamide release from human endothelial cells and platelet activation. Maccarrone M, Bari M, Battista N, Finazzi-Agro A, Blood 2002 100 4040 4048 10.1182/blood-2002-05-1444 12393387 (Pubitemid 35396871)
28. Cannabinoid receptors in acute and chronic complications of atherosclerosis. Mach F, Montecucco F, Steffens S, Br J Pharmacol 2008 153 290 298 10.1038/sj.bjp.0707517 17965744
29. Depression and risk of heart failure among older persons with isolated systolic hypertension. Abramson J, Berger A, Krumholz HM, Vaccarino V, Arch Intern Med 2001 161 1725 1730 10.1001/archinte.161.14.1725 11485505 (Pubitemid 32679547)
30. Guidelines for the Management of Hypertension. Guidelines Subcommittee. World Health Organization-International Society of Hypertension, J Hypertens 1999 17 151 183 10067786
31. Blood pressure as a cardiovascular risk factor: prevention and treatment. Kannel WB, Jama 1996 275 1571 1576 10.1001/jama.1996.03530440051036 8622248 (Pubitemid 26154243)
32. Impact of high-normal blood pressure on the risk of cardiovascular disease. Vasan RS, Larson MG, Leip EP, Evans JC, O'Donnell CJ, Kannel WB, et al. N Engl J Med 2001 345 1291 1297 10.1056/NEJMoa003417 11794147
33. Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Batkai S, Pacher P, Osei-Hyiaman D, Radaeva S, Liu J, Harvey-White J, et al. Circulation 2004 110 1996 2002 10.1161/01.CIR.0000143230.23252.D2 15451779 (Pubitemid 39331913)
34. Hemodynamic profile, responsiveness to anandamide, and baroreflex sensitivity of mice lacking fatty acid amide hydrolase. Pacher P, Batkai S, Osei-Hyiaman D, Offertaler L, Liu J, Harvey-White J, et al. Am J Physiol Heart Circ Physiol 2005 289 533 541 10.1152/ajpheart.00107.2005 15821037 (Pubitemid 41129366)
35. Anandamide content and interaction of endocannabinoid/GABA modulatory effects in the NTS on baroreflex-evoked sympathoinhibition. Seagard JL, Dean C, Patel S, Rademacher DJ, Hopp FA, Schmeling WT, et al. Am J Physiol Heart Circ Physiol 2004 286 992 1000 14615281
36. Effects of endocannabinoids on discharge of baroreceptive NTS neurons. Seagard JL, Hopp FA, Hillard CJ, Dean C, Neurosci Lett 2005 381 334 339 10.1016/j.neulet.2005.02.044 15896495 (Pubitemid 40719182)
37. Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. Cote M, Matias I, Lemieux I, Petrosino S, Almeras N, Despres JP, et al. Int J Obes (Lond) 2007 31 692 699 (Pubitemid 46482358)
38. Elevated endocannabinoid plasma levels are associated with coronary circulatory dysfunction in obesity. Quercioli A, Pataky Z, Vincenti G, Makoundou V, Di Marzo V, Montecucco F, Carballo S, Thomas A, Staub C, Steffens S, Seimbille Y, Golay A, Ratib O, Harsch E, Mach F, Schindler TH, Eur Heart J 2011 32 1369 1378 10.1093/eurheartj/ehr029 21303779
39. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S, Lancet 2005 365 1389 1397 10.1016/S0140-6736(05)66374-X 15836887 (Pubitemid 40523733)
40. An open-label preliminary trial of sertraline for treatment of major depression after acute myocardial infarction (the SADHAT Trial). Sertraline Anti-Depressant Heart Attack Trial. Shapiro PA, Lesperance F, Frasure-Smith N, O'Connor CM, Baker B, Jiang JW, et al. Am Heart J 1999 137 1100 1106 10.1016/S0002-8703(99)70369-8 10347338 (Pubitemid 30040735)
41. Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Taylor CB, Youngblood ME, Catellier D, Veith RC, Carney RM, Burg MM, et al. Arch Gen Psychiatry 2005 62 792 798 10.1001/archpsyc.62.7.792 15997021 (Pubitemid 41002762)
42. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Randomized Trial. Berkman LF, Blumenthal J, Burg M, Carney RM, Catellier D, Cowan MJ, et al. Jama 2003 289 3106 3116 12813116
43. Modulation of anxiety through blockade of anandamide hydrolysis. Kathuria S, Gaetani S, Fegley D, Valino F, Duranti A, Tontini A, et al. Nat Med 2003 9 76 81 10.1038/nm803 12461523 (Pubitemid 36098263)
44. Is there a role for the endocannabinoid system in the etiology and treatment of melancholic depression? Hill MN, Gorzalka BB, Behav Pharmacol 2005 16 333 352 10.1097/00008877-200509000-00006 16148438 (Pubitemid 41404805)
45. American Psychiatric Association, Diagnostic and statistical manual of mental disorders IV American Psychiatric Association, Washington (DC) 4 1994 revised
46. The postmortal accumulation of brain N-arachidonylethanolamine (anandamide) is dependent upon fatty acid amide hydrolase activity. Patel S, Carrier EJ, Ho WS, Rademacher DJ, Cunningham S, Reddy DS, et al. J Lipid Res 2005 46 342 349 15576840 (Pubitemid 40271098)